Market closed

Madrigal Pharmaceuticals/$MDGL

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Ticker

$MDGL
Trading on

Industry

Biotechnology

Employees

376

MDGL Metrics

BasicAdvanced
$6.7B
Market cap
-
P/E ratio
-$25.02
EPS
-0.40
Beta
-
Dividend rate
$6.7B
-0.4
$343.00
$168.25
391K
5.981
5.814
15.217
15.33
-36.19%
-52.25%
-129.76%
83.251
8.65
8.65
-14.589
30.04%
19.52%

What the Analysts think about MDGL

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Madrigal Pharmaceuticals stock.

MDGL Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MDGL Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MDGL

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Madrigal Pharmaceuticals stock?

Madrigal Pharmaceuticals (MDGL) has a market cap of $6.7B as of December 24, 2024.

What is the P/E ratio for Madrigal Pharmaceuticals stock?

The price to earnings (P/E) ratio for Madrigal Pharmaceuticals (MDGL) stock is 0 as of December 24, 2024.

Does Madrigal Pharmaceuticals stock pay dividends?

No, Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders as of December 24, 2024.

When is the next Madrigal Pharmaceuticals dividend payment date?

Madrigal Pharmaceuticals (MDGL) stock does not pay dividends to its shareholders.

What is the beta indicator for Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (MDGL) has a beta rating of -0.4. This means that it has an inverse relation to market volatility.